Stocks · News reference
Coherus Oncology Reveals Special Dividend of Biosimilar Contingent Value Rights; Company Intends To Immediately Commence A Sale Process For The Legacy Biosim Assets
Coherus Oncology, Inc. (NASDAQ:CHRS) ("Coherus", "Coherus Oncology" or the "Company") today announced a special dividend of contingent value rights (each, a "CVR" and collectively, the
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 17, 2026, 9:37 PM
- Checked
- Aug 17, 2026, 9:37 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Coherus Oncology, Inc. (CHRS)
Filed: 2026-08-17 AccNo: 0001104659-26-097951 Size: 467 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgarGuggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $10
Guggenheim analyst Paul Jeng maintains Coherus Oncology (NASDAQ:CHRS) with a Buy and lowers the price target from $12 to $10.
Read original at benzinga